3 High-Dividend Marijuana Stocks to Watch in September 2026
Source: marijuanastocks.com

Cannabis REITs are attracting income-focused investors by providing real estate and financing to licensed cannabis operators rather than directly handling marijuana, with dividend yields described as materially above traditional income investments. The opportunity remains constrained by federal U.S. cannabis illegality, which creates banking, financing, tax and regulatory risks for both operators and their landlords or lenders. The article is sector commentary rather than a company-specific catalyst.
Analysis
The investable exposure is concentrated in IIPR, AFCG and NLCP, where headline dividend yield is better understood as compensation for tenant-credit concentration, illiquid specialized collateral and limited refinancing alternatives—not a conventional REIT income premium. The key earnings variable is rent and interest collection, not broad cannabis sales growth: a single operator restructuring can create simultaneous lost revenue, property impairment, legal expense and a dividend-coverage problem. IIPR has the deeper asset base and diversification, while AFCG carries greater sensitivity to borrower-specific credit outcomes because its mortgage model has less residual real-estate protection in a distressed workout.
Over the next 1-3 months, sector upside likely requires independently observable evidence of improved operator liquidity—capital raises, cleaner audited financials, lease amendments moving to cash collection, and declining rent receivables—rather than promotional industry commentary. Over 6-18 months, federal banking or regulatory normalization is ambiguous: it should reduce defaults and improve property values, but it also lowers the scarcity value of incumbent high-cost capital and could drive loan prepayments and cap-rate compression. Consensus income screens may underprice this trade-off; a lower yield following credit normalization is not automatically bullish if it reflects reduced spread income faster than lower credit losses.
The contrarian opportunity is selective rather than sector-wide. If distressed assets are marked conservatively and collection rates stabilize, IIPR could rerate as a real-estate recovery rather than a cannabis beta vehicle; however, a dividend cut, another material tenant nonpayment, or rising straight-line rent/receivables would invalidate that thesis quickly. There is no broad cannabis-REIT trade absent current tenant concentration, fixed-charge coverage, lease maturity and debt-covenant data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.05
Key Decisions for Investors
- Maintain no blanket allocation to cannabis REITs; place IIPR, AFCG and NLCP on a credit-monitoring watchlist. Require quarterly cash rent/interest collection above 95%, stable or declining receivables, and dividend coverage from recurring cash flow before initiating exposure.
- Prefer a small long IIPR / short AFCG relative-value position only after verified collection stabilization, with a 3-6 month horizon. IIPR offers relatively better property-backed optionality; AFCG is more exposed to borrower refinancing and credit-loss severity. Exit if IIPR reports a material tenant default or AFCG's credit-loss provisions accelerate.
- Do not buy these names solely for yield. Treat any dividend yield materially above mainstream net-lease REITs as a credit-warning signal; size exposure as distressed/special-situations risk rather than income-equity risk.
- Set an event alert for substantive federal banking or rescheduling legislation. On credible passage, reassess for a short-term long basket in IIPR/NLCP, but hedge with a reduction in AFCG exposure because improved tenant access to bank capital may trigger higher-yield loan prepayments.
More News
- Nvidia's role as AI financier faces first big test as neoclouds take market hit
- Ukraine says Starlink and Starshield high speed restrictions have been lifted
- How This County Made the Data Center Boom Pay Off
- Fact vs. fiction: Doctors share whether peptides are safe and effective
- Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
- Election posters, mass tourism and property: Israel’s footprint in Cyprus